BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 11, 2003
 |  BioCentury  |  Strategy

Reproduction Ardana's way

Despite the importance of reproductive medicine to people's lives, it has been a singularly unrewarding area for new companies. The marketplace is dominated by a few big players: Johnson & Johnson (JNJ), Abbott Laboratories (ABT), Wyeth (WYE) and Serono S.A. (SWX:SEO; SRA). Ardana Ltd. thinks there is room for one more. The company is following a low-risk strategy of in-licensing and reformulating existing compounds for development in the European market, as well as repositioning off-patent niche products for reproductive indications.
Ardana, which was founded in July 2000 and is armed with a fresh £20 million ($32.4 million) raised at the end of July, intends to have one product on the market in Europe in early 2004 and at least five Phase III programs by 2005.
In June, COB received FDA approval for Striant to treat men with a deficiency or absence of endogenous testosterone, including hypogonadism. The product is under review in the U.K to treat hypogonadism. Approvals in other European countries will then...

Read the full 807 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >